Announcements Trials
Browse Landscape

Phase

Phase 2 64Phase 1 38Phase 1/2 20Phase 3 12Phase 2/3 6Phase EARLY_PHASE1 2Phase 4 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2CNS 1

Conditions

Melanoma 2Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 9Biopsy 8Nivolumab 7Radiotherapy 6Specimen Handling 5Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Temozolomide 3Rituximab 3Paclitaxel 3Leukapheresis 3Dexamethasone 3Aspirin 3perflutren 2alovudine 2Vaccines 2Tirzepatide 2Surgical Procedures, Operative 2Positron-Emission Tomography 2Phantoms, Imaging 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Irinotecan 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ipilimumab × 90 days × Clear all
NCT05498792 2026-05-22

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Fox Chase Cancer Center

Phase EARLY_PHASE1 Recruiting
12 enrolled
Dermatologic

Melanoma

NCT05704933 2026-04-06

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
1 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡